Wednesday, July 8, 2026

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

Bright Minds Biosciences is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker DRUG. Primary therapeutic focus areas include Cocaine-Related Disorders, Cocaine Dependence, Nicotine Depen

19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Clinical program

NT-301 1 mg

Phase 1 · other · Tolerability of NT-301 Nasal Spray

NT-301 1 mg for Tolerability of NT-301 Nasal Spray is a Phase 1 program (other) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Internal code NT-301-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
BRIGHT MINDS BIOSCIENCES INC.
Phase
Phase 1
Modality
other
Indication
Tolerability of NT-301 Nasal Spray
Status
completed
Trials
1

Clinical trials